GlassScriptPhysician profile
Jaclyn Wozniuk
NPI 1710381249
$7,075.28
in general payments reported to CMS, 2019-2025
45 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,844 · 2022: $1,346 · 2023: $1,301 · 2024: $1,339 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $939.20 | 2021-2024 | |
| Novo Nordisk INC | $753.24 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $563.67 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $399.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $350.05 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $299.75 | 2021-2024 | Aimovig, Prolia, Evenity |
| Esperion Therapeutics, INC. | $288.69 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $265.88 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $243.11 | 2021-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $213.66 | 2021-2025 | |
| Axsome Therapeutics, INC. | $210.78 | 2023-2025 | Auvelity, Sunosi |
| Astrazeneca Pharmaceuticals LP | $202.31 | 2021-2024 | Farxiga |
| Dexcom, INC. | $198.80 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.16 | 2021-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.79 | 2021-2024 | Xifaxan |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Wozniuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.